Rafael (NYSE:RFL – Get Free Report) and Oncology Pharma (OTCMKTS:ONPH – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.
Valuation and Earnings
This table compares Rafael and Oncology Pharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rafael | $920,000.00 | 119.26 | -$30.52 million | ($0.68) | -3.10 |
| Oncology Pharma | N/A | N/A | N/A | N/A | N/A |
Insider & Institutional Ownership
11.3% of Rafael shares are owned by institutional investors. 32.9% of Rafael shares are owned by company insiders. Comparatively, 18.0% of Oncology Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Rafael has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Comparatively, Oncology Pharma has a beta of -4.93, suggesting that its stock price is 593% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Rafael and Oncology Pharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rafael | 1 | 0 | 0 | 0 | 1.00 |
| Oncology Pharma | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Rafael and Oncology Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rafael | -3,321.74% | -41.27% | -35.32% |
| Oncology Pharma | N/A | N/A | N/A |
Summary
Rafael beats Oncology Pharma on 5 of the 8 factors compared between the two stocks.
About Rafael
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
About Oncology Pharma
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.
Receive News & Ratings for Rafael Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rafael and related companies with MarketBeat.com's FREE daily email newsletter.
